Top Markets
Coin of the day
Synairgen plc Synairgen plc

Synairgen plc

SNG
Rangering i aksjer #40400
Synairgen plc specializes in the research and development of pharmaceutical... Synairgen plc specializes in the research and development of pharmaceutical treatments for various respiratory conditions. Its product pipeline includes SNG001, an inhaled interferon beta currently being developed for COVID-19. The company is also advancing an inhaled form of interferon beta (IFN-ß) through Phase II clinical trials for the management of asthma triggered by common colds and influenza, as well as for the treatment or prevention of chronic obstructive pulmonary disease. Furthermore, Synairgen is developing a LOXL2 inhibitor intended for treating idiopathic pulmonary fibrosis (IPF). To support the development of this LOXL2 inhibitor, the company maintains a licensing and collaboration agreement with Pharmaxis Ltd. Synairgen plc was established in 2004 and is headquartered in Southampton, United Kingdom.
Aksjekurs
$0.01292666
Sist synkronisert: 2025-04-08
Markedsverdi
$157.54K
Endring (1 dag)
6.84%
Endring (1 år)
0.00%
Land
GB
Handel Synairgen plc (SNG)

Kategori

Aksjeprishistorikk for Synairgen plc (SNG)
Høyeste sluttskurs: $0.01 den 2025-04-01

Laveste sluttskurs: $2.04 den 2004-10-01
Aksjeprishistorikk for Synairgen plc fra 2004 til 2026
Årlig aksjeprisytelse
År Ytelse
2025 -66.26%
2024 -44.21%
2023 -52.93%
2022 -92.61%
2021 77.16%
2020 1,567.16%
2019 -48.13%
2018 14.84%
2017 -14.89%
2016 -49.84%
2015 -35.02%
2014 -37.63%
2013 15.10%
2012 50.92%
2011 14.84%
2010 -28.85%
2009 88.33%
2008 -77.12%
2007 -24.86%
2006 -99.32%
2005 209.00%
2004 0.00%
Aksjepris for lignende selskaper eller konkurrenter
Selskap Aksjepris Endring 1år% Land
$517.18 30.63%
US
$857.76 32.66%
NL
$744.96 8.94%
CH
$1.08K -6.68%
KR
$259.89 16.65%
BE